Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyteir Therapeutics, Inc. - Common Stock (NQ:CYT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyteir Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
From Cyteir Therapeutics
Via Business Wire
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire
Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Friday. The Dow traded up 0.93% to 34,439.75 while the NASDAQ rose 1.54% to 13,800.92. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
Cyteir Announces Halt of CYT-0851 Development and Company Dissolution Biotech firm Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced today its decision 
Via Spotlight Growth
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.62% to 34,333.42 while the NASDAQ rose 1.37% to 13,777.52. The S&P 500,... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
From Cyteir Therapeutics
Via Business Wire
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
From Cyteir Therapeutics, Inc.
Via Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
 
Via Benzinga
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
From Cyteir Therapeutics
Via Business Wire
5 Value Stocks In The Healthcare Sector
What are Value Stocks? 
Via Benzinga
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Cyteir Therapeutics
Via Business Wire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. 
Via Benzinga
CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies
From Cyteir Therapeutics
Via Business Wire
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
From Cyteir Therapeutics
Via Business Wire
83 Biggest Movers From Yesterday
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
Via Benzinga
Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights
From Cyteir Therapeutics
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.